Loxapine
Specifications
1977-10-2CAS Number
217-835-3EC Number
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepineIUPAC Name
C18H18ClN3OChemical Formula
327.8 g/molMolecular Weight
loxapine; 1977-10-2; Cloxazepine; Oxilapine; Loxapin; Adasuve; Loxapina; Loxapinum; Hydrofluoride 3170; CL-62362; SUM 3170; SUM-3170; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-; HF 3170; LW 3170; CL 62362; CL 62,362; LER583670J; S 805; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine; DTXSID7023229; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; CHEBI:50841; Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-; CL71,563; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo(b)(1,5)benzoxazepine; Maleate, Loxipine; 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo(9.4.0.0^(3,8))pentadeca-1(11),3(8),4,6,9,12,14-heptaene; 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene; Hydrochloride, Loxapine; RefChem:58497; DTXCID903229; N05AH01; Loxitane intramuscular (as hydrochloride); CL 71,563; Loxitane-c oral suspension (as hydrochloride); 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo(9.4.0.03,8)pentadeca-1(11),3,5,7,9,12,14-heptaene; 217-835-3; Dibenzacepin; Dibenzoazepine; Loxitane; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; S-805; HF3170; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; CHEMBL831; Lossapina [DCIT]; Loxapinum [INN-Latin]; Loxapina [INN-Spanish]; Lossapina; Loxapine [USAN:INN:BAN]; AZ-004; Loxapine (USAN/INN); Staccato loxapine; HSDB 3111; Loxapine (water); Loxapine (DMSO); Adasuve (TN); EINECS 217-835-3; Loxapine (Standard); Loxitane Intramuscular; BRN 0626753; Spectrum_000355; LOXAPINE [HSDB]; LOXAPINE [USAN]; SpecPlus_000823; LOXAPINE [INN]; LOXAPINE [MI]; LOXAPINE [VANDF]; Prestwick0_000132; Prestwick1_000132; Prestwick2_000132; Prestwick3_000132; Spectrum2_001737; Spectrum3_001830; Spectrum5_001857; LOXAPINE [MART.]; LOXAPINE [WHO-DD]; Loxitane-C Oral Suspension; Lopac0_000720; SCHEMBL94146; BSPBio_000204; BSPBio_003479; GTPL205; KBioSS_000835; DivK1c_006919; UNII-LER583670J; SPBio_001814; SPBio_002143; LOXAPINE [ORANGE BOOK]; BPBio1_000226; orb1306268; orb3141379; SCHEMBL29374082; SCHEMBL29482385; SCHEMBL30324780; BDBM22871; KBio1_001863; KBio2_000835; KBio2_003403; KBio2_005971; KBio3_002983; HMS5086L22; MSK10298; PXB45563; EBC-26600; HY-17390R; MFCD00242836; PDSP1_001058; PDSP2_001042; s5197; AKOS030526111; CCG-204805; CS-1105; DB00408; SDCCGSBI-0050698.P003; QTL1_000050; NCGC00021145-01; NCGC00021145-02; NCGC00021145-03; NCGC00021145-04; NCGC00021145-05; NCGC00021145-06; NCGC00021145-07; NCGC00021145-08; NCGC00021145-17; NCGC00021145-23; NCGC00022279-03; NCGC00022279-04; NCGC00022279-05; HY-17390; MS-24900; NS00008936; C07104; D02340; F84888; Q58614; T21629; AB00053735_15; AB00053735_16; EN300-6479125; L001085; BRD-K39915878-036-04-6; BRD-K39915878-036-05-3; BRD-K39915878-036-15-2; BRD-K39915878-036-24-4; BRD-K39915878-036-25-1; 2-Chloro-11-(4-methylpiperazino)dibenz[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazino)benzo[b][1,4]benzoxazepine;succinic acid; 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene; 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaeneSynonyms
